OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER RECEIVING A CDK 4 AND 6 INHIBITOR plus FULVESTRANT AFTER PROGRESSING ON/AFTER PRIOR ENDOCRINE THERAPY: A FRACTIONAL POLYNOMIAL NETWORK META-ANALYSIS

被引：0
|
作者：
Hirst, A. [1 ]
Davie, A. [2 ]
Carter, Cuyun G. [3 ]
Haddad, N. [3 ]
Traore, S. [2 ]
Brufsky, A. [4 ]
Harbeck, N. [5 ]
Pivot, X. [6 ]
机构：
[1] ICON PLC, London, England
[2] Eli Lilly & Co Ltd, Windlesham, Surrey, England
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Univ Munchen LMU, Brustzentrum, Munich, Germany
[6] Paul Strauss Canc Ctr, Strasbourg, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN4
引用
收藏
页码：S421 / S421
页数：1
相关论文
共 50 条
  • [21] Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2-advanced breast cancer: a real-world evidence cohort
    Sanchez-Bayona, Rodrigo
    de Sa, Alfonso Lopez
    Gilarranz, Yolanda Jerez
    de Torre, Ana Sanchez
    Alva, Manuel
    Echavarria, Isabel
    Moreno, Fernando
    Tolosa, Pablo
    Lopez, Blanca Herrero
    de Luna, Alicia
    Lema, Laura
    Casado, Salvador Gamez
    Madariaga, Ainhoa
    Lopez-Tarruella, Sara
    Manso, Luis
    Bueno-Muino, Coralia
    Garcia-Saenz, Jose A.
    Ciruelos, Eva
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (03) : 551 - 559
  • [22] Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2-metastatic breast cancer
    Mayer, Erica L.
    Wander, Seth A.
    Regan, Meredith M.
    DeMichele, Angela M.
    Forero, Andres
    Rimawi, Mothaffar F.
    Ma, Cynthia X.
    Cristofanilli, Massimo
    Anders, Carey K.
    Bartlett, Cynthia Huang
    Koehler, Maria
    Winer, Eric P.
    Burstein, Harold J.
    CANCER RESEARCH, 2018, 78 (04)
  • [23] MONARCH 2: Subgroup analysis of patients receiving abemaciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-advanced breast cancer.
    Neven, Patrick
    Johnston, Stephen R. D.
    Toi, Masakazu
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga Nikolaevna
    Okera, Meena
    Masuda, Norikazu
    Koh, Han A.
    Grischke, Eva-Maria
    Conte, Pier Franco
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla
    Kaufman, Peter A.
    Llombart-Cussac, Antonio
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Phase 2 Study of the CDK4/6 Inhibitor FCN-437c in Combination With Fulvestrant or Letrozole and Goserelin in Patients With HR+, HER2-Advanced Breast Cancer
    Shi, JiaJie
    Li, Wei
    Tong, Zhongsheng
    Zang, Aimin
    Zeng, Xiaohua
    Wang, Shui
    Huang, Tao
    Wang, Ying
    Song, Yanqiu
    Kang, Lihua
    Lv, Zheng
    Shi, Yehui
    Yang, Hua
    Wu, Jing
    Yin, Yongmei
    Liang, Yan
    Tan, Jie
    Ming, Jie
    Yang, Yaping
    Luo, Simin
    Gui, Xiujuan
    Hui, Ai-Min
    Wu, Zhuli
    Tian, Ling
    Yang, Yuchen
    Diao, Lei
    Zhang, Wenjing
    Zhang, Yongjiao
    Liu, Yunjiang
    CANCER RESEARCH, 2023, 83 (05)
  • [25] postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy
    Kalinsky, Kevin
    Layman, Rachel M.
    Kaufman, Peter A.
    Graff, Stephanie L.
    Bianchini, Giampaolo
    Martin, Miguel
    Zhou, Yanhong
    Knoderer, Holly
    Litchfield, Lacey
    Andrew Wander, Seth
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer
    Sammons, Sarah
    Shastry, Mythili
    Dent, Susan
    Anders, Carey
    Hamilton, Erika
    CLINICAL BREAST CANCER, 2020, 20 (01) : 1 - 11
  • [27] Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy
    Kaufman, Peter A.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Price, Gregory L.
    Lin, Yong
    Boye, Mark
    Li, Li
    Gable, Jonathon
    Carter, Gebra Cuyun
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] CDK4/6 inhibitors in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: An updated network meta-analysis and cost-effectiveness analysis
    Zeng, N.
    Han, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S369
  • [29] CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
    Zeng, Ni
    Han, Jiaqi
    Liu, Zijian
    He, Jinlan
    Tian, Kun
    Chen, Nianyong
    CANCERS, 2023, 15 (13)
  • [30] MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer
    Goetz, Matthew
    Toi, Masakazu
    Huober, Jens
    Sohn, Joo Hyuk
    Tredan, Olivier
    Park, Inhae
    Campone, Mario
    Chen, Shin-Cheh
    Manso, Luis Manual
    Paluch-Shimon, Shani
    Freedman, Orit C.
    Andre, Valerie
    Saha, Abhijoy
    van Hal, Gertjan
    Shahir, Ashwin
    Iwata, Hiroji
    Johnston, Stephen R. D.
    O'Shaughnessy, Joyce
    Pivot, Xavier
    Tolaney, Sara
    Hurvitz, Sara
    Llombart, Antonio
    CANCER RESEARCH, 2024, 84 (09)
12345